Skip to main content

Table 1 characteristics of the included studies, overall and in the two subgroups (“true” and ICS-placebos)

From: Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression

  All studies “True” placebos ICS-placebos
N Median Range N Median Range N Median Range
Patients 55 207 (43–1524) 21 219 (56–1524) 34 197.5 (43–753)
Study duration (yr) 55 0.4808 (0.2308–3) 21 0.4615 (0.2308–3) 34 0.5 (0.2308–1)
Mean followup (yr) 55 0.4327 (0.1986–2.2596) 21 0.4296 (0.2184–2.2596) 34 0.4481 (0.1987–0.9024)
Mean age (yr) 54 63.9 (58.8–68.6) 21 64.9 (58.8–68.2) 33 63.5 (60–68.6)
Males (%) 55 74.4 (32.9–100) 21 75 (32.9–94.2) 34 72.9 (51.6–100)
Smokers (%) 45 43.4 (16.9–63) 19 39.7 (23–63) 26 44.65 (16.9–56)
Mean pack-years 44 44 (29.4–60.2) 18 43.75 (31.6–56.1) 26 44.3 (29.4–60.2)
Mean FEV-1 50 50.25 (36–73.2) 20 47.8 (36–73.2) 30 52.6 (40.3–71.5)
Mean SGRQ 28 46.52 (33.1–55.6) 10 47.55 (42.59–55.6) 18 46.07 (33.1–52)